Simergent

Simergent

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Simergent is a private, pre-revenue medical device startup founded in 2019 and based in San Francisco, developing the Archimedes™ automated peritoneal dialysis system. The device is engineered to be more patient-centric, with features targeting reduced peritonitis risk, lower fill/drain pressures, minimal setup time, and enhanced mobility to allow a more normal life. Led by a team with deep expertise in PD device development and nephrology, and backed by incubators and venture capital, the company is positioning itself to capture share in the large and growing global home dialysis market, particularly in cost-sensitive emerging regions.

NephrologyEnd-Stage Renal Disease (ESRD)

Technology Platform

Archimedes™ automated peritoneal dialysis (APD) system featuring patented low-pressure fill/drain cycles, patented solution line connectors for reduced infection risk, and a user-centric design for mobility and ease of use.

Opportunities

The massive and growing global ESRD population, particularly in cost-sensitive emerging markets like China, India, and Mexico, presents a major opportunity for an affordable, patient-preferred home dialysis device.
The broader healthcare trend shifting care from clinics to the home creates strong tailwinds in developed markets as well.

Risk Factors

Key risks include the unproven clinical benefit of its design features (especially for peritonitis reduction), the significant challenge of obtaining regulatory clearances, and competing against large, entrenched incumbents with vast resources and established distribution networks.

Competitive Landscape

The market is dominated by large, established players like Baxter International and Fresenius Medical Care, which offer their own APD cyclers. Simergent's competition is based on a differentiated design targeting superior usability, patient comfort, and potential safety benefits, aiming to capture share in niche and emerging markets first.